Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in the Treatment of Symptoms of Vulvovaginal Atrophy in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Estradiol (Primary)
- Indications Atrophic vaginitis; Menopausal syndrome
- Focus Registrational; Therapeutic Use
- Acronyms VENUS
- Sponsors Warner Chilcott
- 11 Apr 2022 Primary end-points were amended. Form of the drug was changed from gel to cream
- 24 Apr 2012 Actual patient number changed from 684 to 722 as reported by ClinicalTrials.gov (Parent: NCT01400776).
- 24 Apr 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov (Parent: NCT01400776).